Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
Saved in:
| Title: | Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). |
|---|---|
| Authors: | van Akkooi ACJ; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands. a.v.akkooi@nki.nl., Hieken TJ; Mayo Clinic, Rochester, MN, USA., Burton EM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ariyan C; Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Asero SVMA; Azienda di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Italy., Blank CU; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Block MS; Mayo Clinic, Rochester, MN, USA., Boland GM; Massachusetts General Hospital, Boston, MA, USA., Caraco C; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Chng S; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Davidson BS; Northside Hospital Cancer Institute, Atlanta, GA, USA., Duprat Neto JP; AC Camargo Cancer Center, São Paulo, Brazil., Faries MB; The Angeles Clinic, Cedars Sinai Medical Center, Los Angeles, CA, USA., Gershenwald JE; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grunhagen DJ; Erasmus MC - Cancer Institute, Rotterdam, The Netherlands., Gyorki DE; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Han D; Oregon Health and Science University, Portland, Oregon, USA., Hayes AJ; Royal Marsden NHS Foundation Trust, London, UK., van Houdt WJ; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Karakousis GC; Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Klop WMC; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, St. Leonards, NSW, Australia.; The Mater Hospital, North Sydney, NSW, Australia., Lowe MC; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, St. Leonards, NSW, Australia.; The Mater Hospital, North Sydney, NSW, Australia., Olofsson Bagge R; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Pennington TE; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Sondak VK; Moffit Cancer Center, Tampa, Florida, USA., Tawbi H; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Testori AAE; Skin Oncology Division, Image Regenerative Clinic, Milan, Italy., Tetzlaff MT; University of California San Francisco (UCSF), San Francisco, CA, USA., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; The Mater Hospital, North Sydney, NSW, Australia., Zager JS; Moffit Cancer Center, Tampa, Florida, USA., Zuur CL; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, The Netherlands., Wargo JA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, St. Leonards, NSW, Australia.; The Mater Hospital, North Sydney, NSW, Australia., Ross MI; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Corporate Authors: | International Neoadjuvant Melanoma Consortium (INMC) |
| Source: | Annals of surgical oncology [Ann Surg Oncol] 2022 Jun; Vol. 29 (6), pp. 3694-3708. Date of Electronic Publication: 2022 Jan 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1534-4681 |
|---|---|
| DOI: | 10.1245/s10434-021-11236-y |
